866-997-4948(US-Canada Toll Free)

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Published By :

Transparency Market Research

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 152 Pages

Hematological Malignancies Market: Overview

This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers of hematology cancer drugs, raw material suppliers, cancer drug processing companies, and new players planning to enter the market. It further presents qualitative and quantitative analysis of the global hematological malignancies market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information.

Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the global hematological malignancies market in major countries globally such as the U.S., Canada, Germany, France, United Kingdom, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the hematological malignancies with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section, further, comprises impact factors such as drivers, restraints, and opportunities for the global hematological malignancies market. These factors would aid the stakeholders in establishing a strong foothold in the global hematological malignancies market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the hematological malignancies market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market. Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%)

Hematological Malignancies Market: Segmentation

The hematological malignancies market has been segmented as Disease condition type, therapy type, distribution channel and geography. Based on disease condition, the market has been segmented into leukemia, lymphoma and myeloma. Likewise, on basis of therapy the market has been categorized into chemotherapy, immunotherapy and targeted therapy. Hospital pharmacies, medical stores and e-commerce platform are included into the market by distribution channel.

Geographically, the hematological malignancies market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the hematological malignancies market in various regions has been provided in this section.

This report also includes various ups and downs about particular country or geography that has impacted the overall market globally. The report provides a detailed outline/blueprint of the hematological malignancies market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market.

Companies mentioned in the report

The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include AbbVie, Inc., Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, and Novartis AG.

The global hematological malignancies market has been segmented into:

Global Hematological Malignancies Market, by Disease Condition

  • Leukemia
  • Lymphoma
  • Myeloma

Global Hematological Malignancies Market, by Therapy

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

Global Hematological Malignancies Market, by Distribution Channel

  • Hospital Pharmacies
  • Medical Stores
  • E-commerce Platform

Global Hematological Malignancies Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of APAC
  • Latin America (LATAM)
  • Brazil
  • Mexico
  • Rest of LATAM
  • Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA

1. Preface
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objectives
1.4. Key Questions Answered

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Acronyms Used
2.3. Research Methodology

3. Executive Summary
3.1. Global Hematological malignancies Market Snapshot
3.2. Market Opportunity Map

4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Death Rate of Leukemia, by Country
4.4. Death Rate of Cancer, by Country

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Opportunity Analysis
5.6. Porter’s Analysis
5.7. Pipeline Analysis (Phase III) till 2024

6. Global Hematological Malignancies Market Analysis, by Disease Condition
6.1. Key Findings
6.2. Introduction
6.3. Leukemia
6.4. Lymphoma
6.5. Myeloma
6.6. Key Trends
6.7. Market Attractiveness Analysis

7. Global Hematological Malignancies Market Analysis, by Therapy
7.1. Key Findings
7.2. Introduction
7.3. Chemotherapy
7.4. Immunotherapy
7.5. Targeted Therapy
7.6. Key Trends
7.7. Market Attractiveness Analysis

8. Global Hematological Malignancies Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Hospital Pharmacies
8.4. Medical Stores
8.5. E-commerce Platform
8.6. Key Trend Analysis
8.7. Market Attractiveness Analysis

9. Global Hematological Malignancies Market Analysis, by Region
9.1. North America
9.2. Europe
9.3. Asia Pacific
9.4. Latin America
9.5. Middle East & Africa
9.6. Market Attractiveness Analysis

10. North America Hematological malignancies Market Analysis
10.1. North America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
10.2. North America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
10.3. North America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
10.4. North America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
10.5. North America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

11. Europe Hematological Malignancies Market Analysis
11.1. Europe Hematological Malignancies Market Size Forecast, By Country, 2016-2024
11.2. Europe Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
11.3. Europe Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
11.4. Europe Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
11.5. Europe Hematological Malignancies Market Attractiveness Analysis, 2016-2024

12. Asia Pacific Hematological Malignancies Market Analysis
12.1. Asia Pacific Hematological Malignancies Market Size Forecast, By Country, 2016-2024
12.2. Asia Pacific Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
12.3. Asia Pacific Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
12.4. Asia Pacific Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
12.5. Asia Pacific Hematological Malignancies Market Attractiveness Analysis, 2016-2024

13. Latin America Hematological Malignancies Market Analysis
13.1. Latin America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
13.2. Latin America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
13.3. Latin America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
13.4. Latin America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
13.5. Latin America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

14. Middle East & Africa Hematological Malignancies Market Analysis
14.1. Middle East & Africa Hematological Malignancies Market Size Forecast, By Country, 2016-2024
14.2. Middle East & Africa Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
14.3. Middle East & Africa Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
14.4. Middle East & Africa Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
14.5. Middle East & Africa Hematological Malignancies Market Attractiveness Analysis, 2016-2024

15. Competitive Landscape
15.1. Hematological Malignancies Market Share Analysis By Company (2015)
15.2. Competition Matrix
15.2.1. Teva Pharmaceutical Industries Ltd.
15.2.2. GlaxoSmithKline plc
15.2.3. Johnson & Johnson
15.2.4. Bristol Myers Squibb
15.2.5. F. Hoffmann-La Roche Ltd. 
15.2.6. Merck & Co., Inc. 
15.2.7. Novartis AG 
15.2.8. Pfizer, Inc. 

16. Company Profiles
16.1. AbbVie, Inc.
16.1.1. Company Details
16.1.2. Company Description
16.1.3. Business Overview
16.1.4. SWOT Analysis
16.1.5. Financial Analysis
16.1.6. Strategic Overview
16.2. Bristol-Myers Squibb Company
16.2.1. Company Details
16.2.2. Company Description
16.2.3. Business Overview
16.2.4. SWOT Analysis
16.2.5. Financial Analysis
16.2.6. Strategic Overview
16.3. Celgene Corporation
16.3.1. Company Details
16.3.2. Company Description
16.3.3. Business Overview
16.3.4. SWOT Analysis
16.3.5. Financial Analysis
16.3.6. Strategic Overview
16.4. F. Hoffmann-La Roche Ltd.
16.4.1. Company Details
16.4.2. Company Description
16.4.3. Business Overview
16.4.4. SWOT Analysis
16.4.5. Financial Analysis
16.4.6. Strategic Overview
16.5. GlaxoSmithKline plc
16.5.1. Company Details
16.5.2. Company Description
16.5.3. Business Overview
16.5.4. SWOT Analysis
16.5.5. Financial Analysis
16.5.6. Strategic Overview
16.6. Johnson & Johnson
16.6.1. Company Details
16.6.2. Company Description
16.6.3. Business Overview
16.6.4. SWOT Analysis
16.6.5. Financial Analysis
16.6.6. Strategic Overview
16.7. Novartis AG
16.7.1. Company Details
16.7.2. Company Description
16.7.3. Business Overview
16.7.4. SWOT Analysis
16.7.5. Financial Analysis
16.7.6. Strategic Overview
16.8. Pfizer, Inc.
16.8.1. Company Details
16.8.2. Company Description
16.8.3. Business Overview
16.8.4. SWOT Analysis
16.8.5. Financial Analysis
16.8.6. Strategic Overview
16.9. Teva Pharmaceutical Industries Ltd.
16.9.1. Company Details
16.9.2. Company Description
16.9.3. Business Overview
16.9.4. SWOT Analysis
16.9.5. Financial Analysis
16.9.6. Strategic Overview

List of Table

TABLE 1 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Pipeline Molecule, till 2024
TABLE 2 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 3 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Therapy, 2016–2024
TABLE 4 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 5 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Region, 2016–2024
TABLE 6 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 7 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 8 North America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 9 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 10 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 11 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 12 Europe Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 13 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 14 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 15 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 16 Asia Pacific Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 17 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 18 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 20 Latin America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 21 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 22 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 23 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 24 MEA Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024

List of Chart

FIG. 1 Global Hematological Malignancies Market Value Share Analysis, by Disease Condition, 2015 and 2024
FIG. 2 Global Leukemia Market Revenue (US$ Mn), 2014–2024
FIG. 3 Global Lymphoma Market Revenue (US$ Mn), 2014–2024
FIG. 4 Global Myeloma Market, Revenue (US$ Mn), 2014–2024
FIG. 5 Hematological Malignancies Market Attractiveness Analysis, by Disease Condition, 2015
FIG. 6 Global Hematological Malignancies Market Value Share Analysis, by Therapy, 2015 and 2024
FIG. 7 Global Chemotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 8 Global Immunotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 9 Global Targeted Therapy Market, Revenue (US$ Mn), 2014–2024
FIG. 10 Hematological Malignancies Market Attractiveness Analysis, by Therapy, 2015
FIG. 11 Global Hematological Malignancies Market Value Share Analysis, by Distribution Channel, 2015 and 2024
FIG. 12 Global Hospital Pharmacies Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global Medical Stores Market Revenue (US$ Mn), 2014–2024
FIG. 14 Global E-commerce Market, Revenue (US$ Mn), 2014–2024
FIG. 15 Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel, 2015
FIG. 16 North America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 17 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 18 APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 20 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 21 Global Hematological Malignancies Market Attractiveness Analysis, by Region
FIG. 22 U.S. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 23 Canada Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 24 North America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 25 North America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 26 North America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 27 North America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 28 Germany Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 29 France Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 30 The U.K. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 31 Italy Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 32 Spain Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 33 Rest of Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 34 Europe Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 35 Europe Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 36 Europe Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 37 Europe Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 38 Japan Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 39 China Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 40 India Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 41 Rest of APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 42 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 43 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Disease Condit
FIG. 44 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 45 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 46 Brazil Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 47 Mexico Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 48 Rest of LATAM Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 49 Latin America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 50 Latin America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 51 Latin America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 52 Latin America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 53 South Africa Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 54 Saudi Arabia Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 55 Rest of MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 56 MEA Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 57 MEA Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 58 MEA Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 59 MEA Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 60 Hematological Malignancies Market Share Analysis, by Company (2015)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *